Contact us

Contact: Gary Pattison, Group Managing Director
on (02) 9955 9500

Gary Pattison

Group Managing Director

Level 2, 72 Christie Street,
St Leonards, NSW 2065
Australia

Ph: +612 9955 9500

X Close

FDA approves first-of-kind device to treat obesity

January 15, 2015

​The U.S. Food and Drug Administration today approved the Maestro Rechargeable System for certain obese adults, the first weight loss treatment device that targets the nerve pathway between the brain and the stomach that controls feelings of hunger and fullness.  

The Maestro Rechargeable System, the first FDA-approved obesity device since 2007, is approved to treat patients aged 18 and older who have not been able to lose weight with a weight loss program, and who have a body mass index of 35 to 45 with at least one other obesity-related condition, such as type 2 diabetes.

BMI, which measures body fat based on an individual’s weight and height, is used to define the obesity categories. According to the Centers for Disease Control and Prevention, more than one-third of all U.S. adults are obese, and people with obesity are at increased risk of heart disease, stroke, type 2 diabetes and certain kinds of cancer.

More here

 

« Back to articles